Abstract
Thymustimulin (TP-1), a thymic extract, has been widely studied for its capacity to induce T-cell proliferation and differentiation. TP-1 has also been shown to exert a stimulatory effect on haematopoiesis both in animal models and in human beings in vivo. In the present set of experiments, we have evaluated the effects of five different fractions of TP-1 on haematopoietic recovery of mice treated with cyclophosphamide (CP), compared to TP-1 in toto. Administration of two different doses (1 and 10 mg/kg) of any of the five TP-1 fractions for 4 consecutive days, together with CP (30 mg/kg), showed that fractions No. 2 (F2), No. 4 (F4) and No. 5 (F5), but not No. 1 (F1) or No. 3 (F3), exerted a protective effect on some of the haematopoietic parameters altered by CP treatment; none of the 5 TP-1 fractions, however, showed the same activity profile as TP-1 in toto. These findings indicate that, in such an experimental model, TP-1 exerts a more complete protective effect on chemotherapy-induced myelotoxicity than any single TP-1 fraction evaluated in the present study.
| Original language | English |
|---|---|
| Pages (from-to) | 53-62 |
| Number of pages | 10 |
| Journal | International Journal of Immunotherapy |
| Volume | 12 |
| Issue number | 3-4 |
| Publication status | Published - 1996 |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
In vivo effects of five different fractions of thymustimulin on haematopoietic recovery of mice treated with cyclophosphamide. / Balleari, E.; Bason, C.; Gotta, F.; Massa, G.; Battaglia, A.; Ghio, R.
In: International Journal of Immunotherapy, Vol. 12, No. 3-4, 1996, p. 53-62.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - In vivo effects of five different fractions of thymustimulin on haematopoietic recovery of mice treated with cyclophosphamide
AU - Balleari, E.
AU - Bason, C.
AU - Gotta, F.
AU - Massa, G.
AU - Battaglia, A.
AU - Ghio, R.
PY - 1996
Y1 - 1996
N2 - Thymustimulin (TP-1), a thymic extract, has been widely studied for its capacity to induce T-cell proliferation and differentiation. TP-1 has also been shown to exert a stimulatory effect on haematopoiesis both in animal models and in human beings in vivo. In the present set of experiments, we have evaluated the effects of five different fractions of TP-1 on haematopoietic recovery of mice treated with cyclophosphamide (CP), compared to TP-1 in toto. Administration of two different doses (1 and 10 mg/kg) of any of the five TP-1 fractions for 4 consecutive days, together with CP (30 mg/kg), showed that fractions No. 2 (F2), No. 4 (F4) and No. 5 (F5), but not No. 1 (F1) or No. 3 (F3), exerted a protective effect on some of the haematopoietic parameters altered by CP treatment; none of the 5 TP-1 fractions, however, showed the same activity profile as TP-1 in toto. These findings indicate that, in such an experimental model, TP-1 exerts a more complete protective effect on chemotherapy-induced myelotoxicity than any single TP-1 fraction evaluated in the present study.
AB - Thymustimulin (TP-1), a thymic extract, has been widely studied for its capacity to induce T-cell proliferation and differentiation. TP-1 has also been shown to exert a stimulatory effect on haematopoiesis both in animal models and in human beings in vivo. In the present set of experiments, we have evaluated the effects of five different fractions of TP-1 on haematopoietic recovery of mice treated with cyclophosphamide (CP), compared to TP-1 in toto. Administration of two different doses (1 and 10 mg/kg) of any of the five TP-1 fractions for 4 consecutive days, together with CP (30 mg/kg), showed that fractions No. 2 (F2), No. 4 (F4) and No. 5 (F5), but not No. 1 (F1) or No. 3 (F3), exerted a protective effect on some of the haematopoietic parameters altered by CP treatment; none of the 5 TP-1 fractions, however, showed the same activity profile as TP-1 in toto. These findings indicate that, in such an experimental model, TP-1 exerts a more complete protective effect on chemotherapy-induced myelotoxicity than any single TP-1 fraction evaluated in the present study.
UR - http://www.scopus.com/inward/record.url?scp=0030403489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030403489&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0030403489
VL - 12
SP - 53
EP - 62
JO - International Journal of Immunotherapy
JF - International Journal of Immunotherapy
SN - 0255-9625
IS - 3-4
ER -